Hoth Therapeutics Inc (HOTH) Actualités

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical...

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ PR Newswire NEW YORK...

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial PR Newswire NEW YORK, Sept...

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment PR Newswire NEW...

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Expands Clinical Trial for Cancer Patients PR Newswire NEW YORK, July 16, 2024 Three New...

Form ARS - Annual Report to Security Holders